Chemical Strategy to Translate Genetic/Epigenetic Mechanisms to Breast Cancer Therapeutics
Final rept. 1 Jul 2010-30 Jun 2014
CALIFORNIA UNIV SAN DIEGO LA JOLLA OFFICE OF CONTRACT AND GRANT ADMINISTRATION
Pagination or Media Count:
Our project aims to use a molecular signature strategy to develop new therapeutics against metastatic breast cancer by targeting the Epithelial-to-Mesenchymal Transition EMT pathway. The project has been pursued in a step-wise fashion We first used RNA-seq to define the molecular signature linked to the gene expression program associated with EMT. We next conducted chemical screening by following the EMT program on a novel technology platform we developed. After successful accomplishment of the first two steps, we selected a panel of leading compounds identified from the initial screen to test on cell and animal models to evaluate their effects in inhibit breast cancer metastasis. At the conclusion of the project, we have confirmed the functional property of identified compounds in inhibiting specific EMT-associated gene expression program on our model cell line. However, as we pointed out in our previous annual reports, we may have sufficient time to compete the study on animal models, which takes time. Importantly, the support from DOD has played a vital role for us to initiate this important project and we intend to continue the project with whatever resources we can identify in the future.
- Anatomy and Physiology
- Medicine and Medical Research